McAnaney Adam sold $216K of OSCR

McAnaney Adam (Chief Legal Officer) sold 9,859 shares of Oscar Health, Inc. (OSCR) at an average of $21.94 ($21.74–$22.45, $0.22M total) across 2 trades on 2026-06-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · McAnaney Adam
Published Jun 4, 2026, 8:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 4:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$OSCR
Bearish
medium confidence
Mentioned
$OSCR
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OSCRBearishLow
01

Why it matters

The disclosed sale adds transparency but is unlikely to move the stock significantly.

02

Market read

Provides fresh insider transaction data; modest relevance for short‑term traders.

03

What to watch

Potential tax‑loss harvesting or diversification unrelated to company outlook.

Relevance 3/10Novelty 3/10Timing: filing date 2026-06-04, after‑hours

Background

Form 4 filings disclose insider transactions; a 10b5‑1 plan sale is pre‑arranged and often neutral.

Company-level read

Ticker impact

$OSCRBearishMedium confidence
Context

Chief Legal Officer sold 9,859 shares for $216K via 10b5-1 plan, disclosed in Form 4 filing.

Expected impact

slight downward pressure as market absorbs insider sell.

Evidence & confidence

The sale size is modest but disclosed via a 10b5‑1 plan, which can prompt short‑term selling.

Market effects

Minimal impact on health‑tech sector; insider activity is routine.

No broader regional effect.

Limited to Oscar Health investors.

Counterpoint

The sale could be purely portfolio‑rebalancing, not a negative signal.

Key entities

  • Oscar Health, Inc.

    US‑listed health‑tech insurer (ticker OSCR).

  • McAnaney Adam

    Chief Legal Officer of Oscar Health, insider reporter.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$UNHMed

Medicare, Medicaid Overhaul Targets Fraudulent Billing and Unauthorized Marketplace Enrollments

CMS proposed reforms to combat fraud in Medicare, Medicaid, CHIP, and the Health Insurance Marketplace, aiming to save $90B over 10 years. The rule strengthens oversight, requires self-reporting of overpayments, and increases transparency. Managed care stocks fell, including UNH, HUM, CVS, CLOV, CNC, MOH, ELV, and OSCR. Medicare anti-fraud efforts saved $41.9B in 2025, with a $22.30 return per dollar spent.

$OSCRHighAI 8/10

What Oscar Health (OSCR) Said on Its Q3 Earnings Call

Oscar Health (OSCR) reported Q3 improvements in medical loss ratio (84%) and SG&A expense ratio (14%). The company raised its 2026 outlook, expecting $850M-$950M in earnings from operations and $19B-$19.3B in revenue. Membership grew 27% YoY to 2.7M, but is expected to decline to 2.5M by year-end due to disenrollments. Oscar plans to expand its footprint and products for 2027.

$OSCRMed

Oscar Health Inc (OSCR) Q3 2026 Earnings Call Highlights: Record Profitability, Raised

Oscar Health (OSCR) reported Q3 2026 earnings with record profitability and raised guidance. Membership declined due to CMS reviews, with more disenrollments expected. Q4 SG&A expenses are projected to rise due to seasonal spending. CEO Mark Bertolini and CFO Richard Blackley discussed market share gains, utilization trends, and CMS program integrity initiatives. The company anticipates stable membership and market growth despite competitive pressures and regulatory uncertainties.

$OSCRHighAI 8/10

Oscar Health (OSCR) Q3 2026 Earnings Call Transcript

Oscar Health (OSCR) reported Q3 2026 revenue of $5.1B, up 70% YoY, with membership at 2.7M, up 27% YoY. Net income was $167.3M, reversing a prior-year loss. The company raised full-year guidance for revenue, earnings, and adjusted EBITDA. Management highlighted expansion into new markets, product launches, and operational efficiencies.

$HCAMed

Hospital Stocks Soared as Democrats Took Congress

HCA Healthcare (HCA) rose 10.34% to $510.70 on November 4, 2026, following Democratic gains in the U.S. election. Investors anticipate potential policy changes favoring hospitals and Medicaid insurers. Universal Health Services (UHS) and Tenet Healthcare (THC) also saw significant gains. HCA's stock is now valued at $106.68 billion, but analysts warn of potential downside risks if policy changes do not materialize.